Navigation Links
Trio of studies support use of PET/CT scans as prostate cancer staging tool
Date:10/21/2011

ROCHESTER, Minn. -- Recent studies have suggested that C-11 choline positron emission tomography/computerized tomography (PET/CT) scans can be utilized as a staging and potentially therapeutic tool in prostate cancer. The results of three studies, released today during a meeting of the North Central Section of the American Urological Association (http://www.ncsaua.org/default.aspx), validate findings in Europe and expand the potential use of C-11 choline PET scans.

One study found that C-11 choline PET/CT scans can be used as a staging tool rather than multiple x-rays, but is not necessarily better. Two additional studies support the favorable claims made in recent medical literature about the use of PET scans to evaluate patients with recurrent prostate cancer. These findings are important because distinguishing localized disease recurrence from systemic recurrence is a vital step in optimizing treatment following primary treatment failure.

"Taken together, the three studies presented today represent an important validation of the C-11 choline PET/CT scan as a staging tool for patients with prostate cancer," says R. Jeffrey Karnes, M.D. (http://www.mayoclinic.org/bio/12463493.html), senior author of all three papers. "We believe the use of these scans can improve the staging and treatment of this common form of cancer, while potentially reducing the cost of delivering the best possible care."

Positron emission tomography is an imaging test that uses a small amount of radioactive material to reveal how tissues and organs are functioning. A C-11 choline PET scan involves the injection into a vein of a small amount of C-11 choline, a radioactive form of the vitamin choline. Clinicians then use a scanner and computer to make detailed pictures of areas where the C-11 choline collects. Since cancer cells take up more C-11 choline than normal cells, the pictures can be used to find cancer in the body.

Summary of the Three Studies

"Initial Staging for High-Risk Prostate Cancer: Is there a Role for C-11 Choline PET Scan?" The findings suggest that C11-choline PET is an accurate diagnostic tool when used as the initial staging modality prior to definitive treatment and could potentially eliminate the need for CT and/or bone scans.

"Detection of Consolidated Disease Recurrences of Prostate Cancer by C-11 Choline PET Scan: Results Confirmed by Surgical Resection" This study found that a C-11 choline PET scan is an accurate diagnostic tool for detecting localized disease recurrences that, in select cases, are suitable for salvage surgical resection.

"Operational Characteristics of C-11 Choline PET Scan for Prostate Cancer Patients with Biochemical Recurrence Following Initial Treatment" The operational performance of C11-choline PET for evaluating patients with recurrent prostate cancer supports the favorable claims regarding this technology. The use of C-11-choline PET substantially enhances the rate of prostate cancer lesion detection by approximately 30% beyond what can be garnered using conventional imaging technologies.


'/>"/>
Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Hospital Programs to Reduce Antibiotic Resistance Working: Studies
2. Start HIV Drug Treatment Early in Patients With TB: Studies
3. Researchers review studies on CCSVI-MS link
4. Clemson researchers using interactive vision tool for driving studies
5. FDA Focuses on Silicone Breast Implant Safety Studies
6. SHSU studies GPS monitoring of Arizona sex offenders
7. Studies shed light on hand hygiene knowledge and infection risk in hospitals and elementary schools
8. WU studies obesity, cancer link with $9.2 million grant
9. Minority participants crucial to effective aging studies
10. Studies examine impact of media use among youth, recommend preventative measures
11. Related studies point to the illusion of the artificial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: